Rice University researchers created a cell-based "living bandage" that continuously secretes three healing cytokines (IL-10, IL-12 and TGF-β) from engineered cells housed in a protective, permeable patch. In rodent and pig studies the device sped wound healing and activated regeneration-related genes. The platform is customizable and may one day support electronic or optogenetic control, but it remains preclinical and has not yet been tested in humans.
Living Bandage Delivers Healing Proteins — Rice University Patch Speeds Wound Repair in Animal Tests
Scientists unveil 'living bandage' that could dramatically speed wound healing
Researchers at Rice University have developed a cell-based "living bandage" designed to accelerate healing of serious wounds by continuously delivering therapeutic proteins directly at the injury site, according to reporting by SWNS and a study in Nature Biomedical Engineering.
How the Patch Works
The device contains engineered cells embedded in a protective, semipermeable enclosure and a specialized hydrogel that helps the patch integrate with the wound surface. The cells are programmed to produce and secrete three healing cytokines — IL-10, IL-12 and transforming growth factor–beta (TGF-β) — providing a steady, localized source of signals that regulate inflammation and tissue repair.
Advantages Over Conventional Treatments
Unlike topical ointments or injections, which can wash away or degrade quickly, the living bandage acts like a continuous, localized factory for fragile therapeutic proteins. The protective material permits nutrients and therapeutic molecules to pass while shielding the engineered cells from immune attack, extending the duration and consistency of cytokine delivery at the wound site.
"By maintaining a consistent presence of these signaling molecules at the wound site, we can more effectively engage the body’s natural healing response," the scientists said.(iStock)
"The findings show how continuous, localized cytokine delivery can support key biological pathways involved in tissue repair," said Professor Omid Veiseh, faculty director of the Rice Biotech Launch Pad and leader of the laboratory development.
Preclinical Results and Readiness
In laboratory studies on rodents and pigs the patch accelerated wound closure and activated gene programs associated with regeneration and immune modulation. Genetic analyses of treated tissue indicated coordinated upregulation of pathways needed for repair, providing a mechanistic explanation for the improved healing observed in animal tests.
Study co-author Christian Schreib, Ph.D., noted that the platform is designed to be customizable: cells can be reprogrammed to produce different combinations of proteins and growth factors tailored to patient needs. Future work may add real-time control methods such as optogenetics or electronic components to tune the timing and dose of cytokine release.
Limitations and Next Steps
The technology is still in an early, preclinical stage and has not been tested in human patients. Additional research is required to assess safety, long-term performance, and regulatory pathways before clinical use.
Source: Study published in Nature Biomedical Engineering; reporting by SWNS.
Help us improve.
